Radiotherapy is a very important clinical treatment means. This article summarizes the latest advancement in the clinical treatment of radiation oncology, including radiophysics, radiobiology and clinical oncology. The aim is to tell the reader the current situation and advances of radiotherapy and its function in comprehensive therapy of oncology.
[1] 殷蔚伯, 余子豪, 徐国镇, 等. 肿瘤放射治疗学[M]. 4版. 北京: 中国协 和医科大学出版社, 2008. Yin Weibo, Yu Zihao, Xu Guozhen, et al. Radiation oncology[M]. 4th ed. Beijing: Chinese Peking Union Medical College Press, 2008.
[2] 刘泰福. 现代放射肿瘤学[M]. 上海: 复旦大学出版社, 2001. Liu Taifu. Modern radiation oncology[M]. Shanghai: Fudan University Press, 2001.
[3] 朱广迎. 放射肿瘤学[M]. 2版. 北京: 科技文献出版社, 2006. Zhu Guangying. Radiation oncolgy[M]. 2nd ed. Beijing: Scientific & Technological Documentation Publishing House, 2006.
[4] 朱广迎, 李晔雄, 夏廷毅, 等. 放射肿瘤学原理与实践[M]. 5版. 天津: 天津科技翻译出版公司, 2012. Zhu Guangying, Li Yexiong, Xia Tingyi, et al. Principle and practice of radiation oncology[M]. 5th ed. Tianjin: Tianjin Science & Technology Translation & Publishing Corporation, 2012.
[5] 胡逸民, 谷铣之. 适形放射治疗——肿瘤放射治疗技术的进展[J]. 中 华放射肿瘤学杂志, 1997, 6(1): 8-11. Hu Yimin, Gu Xianzhi. Conformal radiotherapy: New advances in technology of radiation oncology[J]. Chinese Journal of Radiation Oncolgy,1997, 6(1): 8-11.
[6] 刘泰福. 中国放射肿瘤学的发展[J]. 中华放射肿瘤学杂志, 2000, 9 (1): 5-7. Liu Taifu. New advances in Chinese radiation oncology[J]. Chinese Journal of Radiation Oncolgy, 2000, 9(1): 5-9.
[7] Hong L, Hunt M, Cui C, et al. Intensity-modulated tangential beam irradiation of the intact breast cancer[J]. International Journal of Radiation Oncology·Biology·Physics, 1999, 44(5): 1155-1164.
[8] 于金明, 于安伦, 王亚彬. 临床肿瘤放疗新进展[J]. 国外医学肿瘤学分 册, 1998, 25(5): 291-293. Yu Jinming, Wang Anlun, Wang Yabin, et al. New advances in clinical radiation oncology[J]. Foreign Medical Sciences (Section of Oncology), 1998, 25(5): 291-293.
[9] Lagerwaard F J, Verstegen N E, Haasbeek C J, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer[J]. International Journal of Radiation Oncology·Biology·Physics, 2012, 83(1): 348-353.
[10] Verstegen N E, Lagerwaard F J, Haasbeek C J, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: Comparison with a contemporaneous cohort with pathologically proven disease[J]. Radiotherapy Oncology, 2011, 101 (2): 250-254.
[11] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. Journal of the American Medical Association, 2010, 303(11): 1070-1076.
[12] 董济民, 冯关力. 肿瘤放射增敏研究进展[J]. 陕西医学杂志, 2011, 40(4): 493-494. Dong Jimin, Feng Guanli. New advances in radio sensibilization of oncology[J]. Journal of Shaanxi Medicine, 2011, 40(4): 493-494.
[13] 陆海鹏, 农英高. 抗肿瘤放射增敏剂的临床研究进展[J]. 中国药业, 2012, 21(3): 87-89. Lu Haipeng, Nong Yinggao. New advances in clinical research of radiation sensitizer on oncology[J]. Chinese Medicine, 2012, 21(3): 87- 89.
[14] 张珊文, 肖绍文, 刘长青, 等. 头颈鳞癌p53基因——放疗的临床研 究(附36例报告)[J]. 中华肿瘤杂志, 2005, 27(7): 426. Zhang Shanwen, Xiao Shaowen, Liu Changqing, et al. Clinical research of p53 gene combined with radiotherapy on head and neck squamous carcinoma(a report of 36cases) [J]. Chinese Journal of Oncology, 2005, 27(7): 426.
[15] Pan J J, Zhang S W, Chen C B, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma[J]. Jounal of Clinical Oncology, 2009, 27(5): 799-804.
[16] 夏廷毅. SBRT临床应用结果的思考[J]. 医疗装备, 2009(7): 1-5. Xia Tingyi. Thinking about outcome of SBRT in clinical treatment[J]. Medical Equipment, 2009(7): 1-5.
[17] Chung H T, Lee B, Park E, et al. Can all centers plan intensity modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three dimensional conformal radiotherapy and IMTR for adjuvant chemoradiation for gastric cancer[J]. International Journal of Radiation Oncology · Biology · Physics, 2008, 71(4): 1167.
[18] Hallissey M T, Dunn A A, Ward L C, et al. The second british stomach cancer group trial of adjuvant radiotherapy or chemotherapy in respectable gastric cancer: Five- year follow up[J]. Lancet, 1994, 343(8909): 1309-1312.
[19] MacDonald J S, Smalley S R, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach orgastroesophagea I junction[J]. New England Journal of Medicine, 2001, 345(10): 725-730.
[20] MacDonald J S, Smalley S R, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS)and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: up-date of the results of inter group study INT-0116 (SWOG9008)[C]//Program/Proceedings American Society of Clinical Oncology. Chicago: American Society of Clinical Oncology, 2004．
[21] Kim S, Lim D H, Lee J, et al. An observational study suggesting clinical benefit for adjuvant post operative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach[J]. International Journal of Radiation Oncology·Biology·Physics, 2005, 63(5): 1279-1285.
[22] Francesco F, Francesco C, Marco E, et al. The impact of radiotherapy on survival in respectable gastriccarcinoma: A meta-analysis of literature data[J]. Cancer Treatment Reviews, 2007, 33(8): 729-740.
